Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methylpromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.53 |
| ▸ | GFER | P55789 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.78 |
| ▸ | HTR1A | P08908 | 6/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.78 |
| ▸ | DRD3 | P35462 | 6/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.78 |
| ▸ | DRD1 | P21728 | 5/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.78 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.78 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylpromazine SCHEMBL719590 | 1.00 | GFER (1.00) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| Methylpromazine SCHEMBL21293802 | 0.90 | GFER (0.82) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL15789014 | 0.89 | CHRM2 (0.82) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL15789013 | 0.89 | CHRM2 (0.82) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| Methylpromazine SCHEMBL18994 | 0.88 | CHRM2 (1.00) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| Methylpromazine SCHEMBL29354434 | 0.88 | CHRM2 (1.00) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| Methylpromazine SCHEMBL18993 | 0.88 | CHRM2 (1.00) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| Cyamemazine SCHEMBL15841313 | 0.88 | GFER (0.77) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| Methylpromazine SCHEMBL2774391 | 0.87 | CHRM2 (0.97) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| SCHEMBL21318406 | 0.81 | HTR1A (0.70) | GFERCHRM2HTR1ACHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1472 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050442-A1 | TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER | UNIVERSITÉ COTE D'AZUR (FR) | 2024-02-15 | — | — | US | claimed |
| EP-4255437-A1 | TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER | Centre National de la Recherche Scientifique (FR) | 2023-10-11 | — | — | EP | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| WO-2022122688-A1 | TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-06-16 | — | — | WO | claimed |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2019-04-30 | — | — | US | claimed |
| US-10154856-B2 | Therapeutic substance transfer catheter and method | SILLENDER MARK (AU) | 2018-12-18 | — | — | US | claimed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | claimed |
| EP-3309163-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE Industries, Ltd. (JP) | 2018-04-18 | — | — | EP | claimed |
| CN-107735401-A | Substituted Dihydropyrrolopyrazole Derivatives | 宇部兴产株式会社 | 2018-02-23 | — | — | CN | claimed |
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | claimed |
| EP-0935523-A4 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GEN MILLS INC (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | claimed |
| US-4269835-A | Nasal composition for relieving nasal distress | WHITTLE BARRY J | 1981-05-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050442-A1 | TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER | GRIK5, HTR5A, CYP3A5 | HRH1 2361/4885GFER 1991/4885CHRM2 2329/4885 |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | QDPR, CYP11B2, CYP4F3 | HRH1 988/4885GFER 3834/4885CHRM2 2031/4885 |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | QDPR, CYP11B2, CYP4F3 | HRH1 988/4885GFER 3834/4885CHRM2 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.